At the time of writing the private health insurer’s shares are up 2% to $5.08. This compares to a disappointing 3.3% decline by the ASX 200 index.
Why is the NIB share price pushing higher?
Investors have been buying the company’s shares on Friday after it unveiled a members and community support package in response to the COVID-19 pandemic.
The company’s managing director, Mark Fitzgibbon, explained that NIB and the rest of the industry have an important and critical role to play in helping Australians through this challenging period.
He said: “Many of our members confront profound uncertainty and the threat or reality of unemployment. We are doing as much as we can to help them maintain their cover and more broadly, stay safe and healthy.”
“The crisis has actually presented health insurers and the total private health system with a unique challenge to demonstrate how we can play an enhanced role in our total healthcare system,” he added.
What is NIB’s support package?
According to the release, NIB’s support package includes:
- Expanded coverage for chest, lung, kidney, and bladder or other treatment related to COVID-19 across all levels of hospital cover at no additional cost until the crisis passes. This means more than 300,000 policies or over 560,000 of its members will now have access to COVID-19 treatment who would otherwise not be covered.
- Ability for existing members who are experiencing financial hardship to access special premium relief. This includes the option to suspend their health insurance policy and premium payment for up to six months while remaining covered for COVID-19 related treatment.
- The company is making its specialist health management and emergency assistance team, nibAssist, available 24/7 for members who require COVID-19 medical and non-medical health support.
- A $1 million donation from nib foundation and nib to support charitable initiatives assisting the community during the pandemic. It will also be exploring a range of clinical and community health initiatives to assist in the identification and treatment of those vulnerable or at risk to COVID-19.
Finally, looking ahead, Mr Fitzgibbon added that anticipated savings from the deferral of elective surgery will be considered later this year as part of its next round of premium pricing changes.
Rival Medibank Private Ltd (ASX: MPL) has not yet responded to this, but I suspect it is quite likely to follow suit and support its members with a similar package.
Our experts here at The Motley Fool Australia have just released a fantastic report, detailing 5 dirt cheap shares that you can buy in 2020.
One stock is an Australian internet darling with a rock solid reputation and an exciting new business line that promises years (or even decades) of growth… while trading at an ultra-low price…
Another is a diversified conglomerate trading over 40% off it's high, all while offering a fully franked dividend yield over 3%...
Plus 3 more cheap bets that could position you to profit over the next 12 months!
See for yourself now. Simply click here or the link below to scoop up your FREE copy and discover all 5 shares. But you will want to hurry – this free report is available for a brief time only.
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has recommended NIB Holdings Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.